Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals

European Journal of Clinical Pharmacology

Volumn 68, Issue 8, 2012, Pages 1175-1182

  Teng, Renli ^a   Mitchell, Patrick ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Age; Antiplatelet therapy; Gender; P2Y12 receptor antagonist; Pharmacokinetics; Ticagrelor

Indexed keywords

AR C 124910XX; ATROPINE; DRUG METABOLITE; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; CHEST TIGHTNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEMATOLOGY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VITAL SIGN;

ADENOSINE; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SEX FACTORS; YOUNG ADULT;

EID: 84866517530     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1227-4     Document Type: Article

References (35)

1. Husted S, van Giezen JJJ (2009) Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27:259-274.
2. Brilique, summary of product characteristics, 2010. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001241/WC500100494.pdf Accessed 18 October 2011.
3. BrilintaTM, US full prescribing information, July 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s000lbl.pdf Accessed 10 October 2011.
4. James S, Åkerblom A, Cannon CP et al (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 157:599-605.
5. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057.
6. Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514-1521.
7. Zhou D, Andersson TB, Grimm SW (2011) In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 39:703-710.
8. Ma Q, Lu AY (2011) Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63:437-459.
9. McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56:163-184.
10. MeibohmB, Beierle I, Derendorf H (2002)How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329-342.
11. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33(Suppl 2):6-9.
12. Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018.
13. Bebawy M, Chetty M (2009) Gender differences in P-glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab 10:322-328.
14. Paine MF, Ludington SS, Chen M-L et al (2005) Do men and women differ in proximal small intestinal CYP3A or P-glyoprotein expression? Drug Metab Dispos 33:426-433.
15. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76.
16. Hilmer SN, Shenfield GM, Le Couteur DG (2005) Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 1:151-156.
17. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33-60.
18. Greenblatt DJ, von Moltke LL (2008) Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350-1355.
19. Scandlyn MJ, Stuart EC, Rosengren RJ (2008) Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413-424.
20. He P, Court MH, Greenblatt DJ, von Moltke LL (2005) Genotypephenotype associations of cytochrome P45 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373-387.
21. Butler K, Teng R (2010) Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 70:65-77.
22. Teng R, Butler K (2010) Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 66:487-496.
23. Regitz-Zagrosek V, Seeland U (2011) Sex and gender differences in myocardial hypertrophy and heart failure. Wein Med Wochenschr 161:109-116.
24. Boström G (2006) Chapter 9: habits of life and health. Scand J Pub Health 34(Suppl 67):199-228.
25. Bliden K, Dichiara J, Lawal L et al (2008) The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52:531-553.
26. ICH harmonized tripartite guideline for good clinical practice E6(R1) (1996). Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf Accessed 18 October 2011.
27. Sillén H, Cook M, Davis P (2010) Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2299-2306.
28. Seber GAF, Wild CJ (2003) Unconstrained optimization. In: Seber GAF, Wild CJ (eds) Nonlinear regression. John Wiley & Sons, New Jersey, pp 587-618.
29. Seber GAF, Wild CJ (2003) Computational method for nonlinear least squares. In: Seber GAF, Wild CJ (eds) Nonlinear regression. John Wiley & Sons, New Jersey, pp 619-660.
30. Labarthe B, Théroux P, Angioï M, Ghitescu M (2005) Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46:638-645.
31. Mottino AD, Catania VA (2008) Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 14:7068-7074.
32. Husted S, Emanuelsson H, Heptinstall S et al (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038-1047.
33. Husted S, James S, Becker RC et al (2011) Ticagrelor versus. clopidogrel in elderly patients with acute coronary syndromes - a substudy from prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. J Am Coll Cardiol 57(Suppl 1): e1099.
34. Karavidas A, Lazaros G, Tsiachris D, Pyrgakis V (2010) Aging and the cardiovascular system. Hellenic J Cardiol 51:421-427.
35. Löwenberg EC, Meijers JCM, Levi M (2010) Platelet-vessel wall interaction in health and disease. Neth J Med 68:242-251.